Screening performed up to every 5 years from age 55 using the multi-markerrisk-based screening algorithm for future prostate cancer achieves a high DRand a much lower FPR than using PSA alone, resulting in reductions inoverdiagnosis and overtreatment. This evidence concerns the gene KLK3 and prostate carcinoma.